Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2005-12-21

Original market date: See footnote 1

2005-12-21

Product name:

ENBREL

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02274728

Product Monograph/Veterinary Labelling:

Date: 2021-03-19 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

IMMUNEX CORPORATION
One Amgen Centre Drive
Thousand Oaks
California
United States 91320-1799

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Subcutaneous

Number of active ingredient(s):

1

Schedule(s):

Schedule D ,  Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

92:36.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

L04AB01 ETANERCEPT

Active ingredient group (AIG) number:See footnote5

0151564001

List of active ingredient(s)
Active ingredient(s) Strength
ETANERCEPT 50 MG / ML

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Pharmacovigilance/Monitoring Activity
Registry
Version 4.0.2
Date modified: